Study of Efficacy and Safety of MAS825 in Patients With COVID-19
Public ClinicalTrials.gov record NCT04382651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.
Study identification
- NCT ID
- NCT04382651
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 140 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2020
- Primary completion
- Jan 5, 2021
- Completion
- Apr 20, 2021
- Last update posted
- Aug 9, 2022
2020 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Chula Vista | California | 91911 | — |
| Novartis Investigative Site | Glendale | California | 91206 | — |
| Novartis Investigative Site | Irvine | California | 92697 | — |
| Novartis Investigative Site | La Mesa | California | 91942 | — |
| Novartis Investigative Site | Santa Monica | California | 90404 | — |
| Novartis Investigative Site | Torrance | California | 90503 | — |
| Novartis Investigative Site | Denver | Colorado | 80220 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20037 | — |
| Novartis Investigative Site | Idaho Falls | Idaho | 83404 | — |
| Novartis Investigative Site | Alexandria | Louisiana | 71301 | — |
| Novartis Investigative Site | Baton Rouge | Louisiana | 70809 | — |
| Novartis Investigative Site | Lafayette | Louisiana | 70596 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02115 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02118 | — |
| Novartis Investigative Site | Brooklyn | New York | 11219 | — |
| Novartis Investigative Site | Asheville | North Carolina | 28805 | — |
| Novartis Investigative Site | Columbus | Ohio | 43214 | — |
| Novartis Investigative Site | Bend | Oregon | 97701 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19140 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | Mesquite | Texas | 75149 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04382651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2022 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04382651 live on ClinicalTrials.gov.